Liposomal delivery enhances cutaneous availability of ciclopirox olamine

The present study involves development and investigation of liposomal system for improving skin residence of ciclopirox olamine in cutaneous mycosis. Spherical unilamellar liposomes of ciclopirox olamine were prepared by ethanol injection method. The vesicle size and % entrapment efficiency were in the range of 196 ± 1.73 to 1040.66 ± 7.02 nm and 34.28 ± 4.4 to 54.89 ± 1.9 respectively. The electrokinetic potential varied from -52.4 ± 2.0 to -71.7 ± 1.3 mV. A 32 factorial design was utilized to optimize the concentrations of cholesterol and Phospholipon® 90H. Cholesterol was found to be primarily responsible for the behaviour of the liposomes as compared to the phospholipid. FTIR study revealed that liposomal encapsulation preserved the principal characteristic group of ciclopirox olamine required for antifungal action. In-vitro artificial membrane and ex-vivo excised rat skin studies demonstrated reasonably higher cutaneous deposition of the drug. Liposomes proved interesting tool for maximizing the drug retention in skin, an important requisite in treatment of cutaneous fungal infections.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit Systems of Ornidazole

The objective of the present study was to investigate the applicability of matrix type mucoadhesive oral multiple unit systems (MUS) for sustaining the release of ornidazole in the gastrointestinal tract (GIT). The MUS were prepared by ionotropic gelation method using chitosan and hydroxypropyl methyl cellulose K4M (HPMC K4M) according to 32 factorial designs and were evaluated in vitro and in vivo. The particle size length ranged from 0.78 to 1.30 mm and breadth from 0.76 to 1.30 mm, respectively. The entrapment efficiency was in range of 80 to 96%. The rapid wash-off test was observed faster at intestinal pH 6.8 as compared to acidic pH 1.2. The fluoroscopic study revealed the retention of MUS in GIT for more than 5 hours. The pharmacokinetic parameters Cmax, Tmax, mean residence time (MRT) and area under curve (AUC) of developed MUS were found to be improved significantly (p<0.05) when compared with marketed immediate release tablets each containing 500 mg of drug. This study demonstrates that the MUS could be a good alternative to immediate release tablets to deliver ornidazole and expected to be less irritant to gastric and intestinal mucosa

Validated UV-Vis spectrophotometric method for the estimation of Sorafenib Tosylate in bulk and nanoparticles

It was noticed from the standard databases such as Scopus, PubMed, ScienceDirect, etc. that a limited UV-Vis spectrophotometric method has been reported for estimating Sorafenib (SOR), but no sophisticated analytical methods have been ever reported in any database for estimating SOR in nanoparticles. The present research involved the establishment of an economic, accurate, robust, and precise analytical method for the quantitative determination of SOR in bulk and nanoparticles utilizing a new validated spectrophotometric method. The spectrophotometric analysis was carried out using double-beam&nbsp; ultraviolet-visible spectrophotometer was employed in developing a new method using methanol and water at a ratio of 80:20 v/v and λmax of 265 nm. The technique was verified using the Q2A and Q2B guidelines of ICH. The newly developed UV-Vis method had desired linearity over the range of 2-12 μg/mL; along with excellent precision, accuracy, ruggedness, and robustness characteristics as observed from % RSD values of less than 2. The present study concluded that the developed UV-Vis method has desired linearity, precision, accuracy, ruggedness, and robustness, and will serve as an excellent technique for the determination of sorafenib in both bulk and nanoparticles without the interference of commonly used chemicals or solvents

Validated UV-Vis Spectrophotometric Method for the Estimation of Sorafenib Tosylate in Bulk and Nanoparticles

It was noticed from the standard databases such as Scopus, PubMed, ScienceDirect, etc. that a limited UV-Vis spectrophotometric method has been reported for estimating Sorafenib (SOR), but no sophisticated analytical methods have been ever reported in any database for estimating SOR in nanoparticles. The present research involved the establishment of an economic, accurate, robust, and precise analytical method for the quantitative determination of SOR in bulk and nanoparticles utilizing a new validated spectrophotometric method. The spectrophotometric analysis was carried out using double-beam&nbsp; ultraviolet-visible spectrophotometer was employed in developing a new method using methanol and water at a ratio of 80:20 v/v and λmax of 265 nm. The technique was verified using the Q2A and Q2B guidelines of ICH. The newly developed UV-Vis method had desired linearity over the range of 2-12 μg/mL; along with excellent precision, accuracy, ruggedness, and robustness characteristics as observed from % RSD values of less than 2. The present study concluded that the developed UV-Vis method has desired linearity, precision, accuracy, ruggedness, and robustness, and will serve as an excellent technique for the determination of sorafenib in both bulk and nanoparticles without the interference of commonly used chemicals or solvents

Gradient RP-HPLC Method Development and Validation for Simultaneous Estimation of Paclitaxel and Albendazole

The goal of this research is to provide an accurate and exact technique for estimating Albendazole and Paclitaxel simultaneously utilizing gradient RP-HPLC (high performance liquid chromatography). A UV detector fixed at 230 nm was used to estimate albendazole and paclitaxel simultaneously. As the solvent system, acetonitrile and water in the ratio of 50:50 was used in the presence of 0.1 % trifluoroacetic acid. Mobile phase was run on a Inertsil ODS 3V 150 4.6 mm or equivalent column in Gradient mode at a flow rate of 1.0 mL/min. By this method albendazole and paclitaxel showed 6.199 and 9.684 retention time (Rt) respectively with continuous run upto 25 min. In the prescribed concentration range, the calibration curves for each analyte were determined to be linear (r2 &gt; 0.994). The percentage of recovery was found to be within the limit at each level (98.0 %to 102.0 %). All validation parameters were determined to be acceptable, including system precision, method precision, linearity, range, accuracy, ruggedness, robustness, solution, and mobile phase stability findings. This suggests that the HPLC simultaneous approach for determining albendazole and paclitaxel assays is accurate.